cMET: a prognostic marker in papillary renal cell carcinoma?
The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consor...
Gespeichert in:
| Veröffentlicht in: | Human pathology 2022-03, Vol.121, p.1-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Human pathology |
| container_volume | 121 |
| creator | Erlmeier, Franziska Bruecher, Benedict Stöhr, Christine Herrmann, Edwin Polifka, Iris Agaimy, Abbas Trojan, Lutz Ströbel, Philipp Becker, Frank Wülfing, Christian Barth, Peter Stöckle, Michael Staehler, Michael Stief, Christian Haferkamp, Axel Hohenfellner, Markus Macher-Göppinger, Stephan Wullich, Bernd Noldus, Joachim Brenner, Walburgis Roos, Frederik C. Walter, Bernhard Otto, Wolfgang Burger, Maximilian Schrader, Andres Jan Hartmann, Arndt Mondorf, Yvonne Ivanyi, Philipp Mikuteit, Marie Steffens, Sandra |
| description | The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET− vs. cMET+: pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET−: 2 [4.3%] vs. cMET+: 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival.
•The tyrosine-protein kinase c-Met supports aggressive tumor behavior and plays a decisive role in numerous cellular processes.•Patients' medical history and tumor specimens were collected from n = 197 and n = 110 patients with type 1 and 2 papillary renal cell carcinoma, respectively.•cMET expression did not qualify as a prognostic marker in papillary renal cell carcinoma for overall survival. |
| doi_str_mv | 10.1016/j.humpath.2021.12.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618517766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S004681772100215X</els_id><sourcerecordid>2618517766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-c87541c9d00ac919795c1dadfcdf2ec4d43db9a6a69a5e3424f6ba3dd8db0b8d3</originalsourceid><addsrcrecordid>eNqFkEtLxDAQx4Mouj4-glLw4qU1r6aJCIssvmDFi55DmqSatS-TVthvb8quHrx4mbn8ZuY_PwBOEcwQROxylb2PTa-G9wxDjDKEMwiLHTBDOcEpJwLvghmElKUcFcUBOAxhBSFCOc33wQGhQnBO4Qxc66fbl6tEJb3v3touDE4njfIf1ieuTXrVu7pWfp1426o60baORXnt2q5R82OwV6k62JNtPwKvd7cvi4d0-Xz_uLhZppoIMqSaFzlFWhgIlRZIFCLXyChTaVNhq6mhxJRCMcWEyi2hmFasVMQYbkpYckOOwMVmbwz5OdowyMaFKYtqbTcGiRnieXyTsYie_0FX3ehj9okiXDAqKI9UvqG070LwtpK9d_HttURQTnrlSm71ykmvRFhGvXHubLt9LBtrfqd-fEZgvgFs1PHlrJdBO9tqa5y3epCmc_-c-AZlF42l</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638964948</pqid></control><display><type>article</type><title>cMET: a prognostic marker in papillary renal cell carcinoma?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Erlmeier, Franziska ; Bruecher, Benedict ; Stöhr, Christine ; Herrmann, Edwin ; Polifka, Iris ; Agaimy, Abbas ; Trojan, Lutz ; Ströbel, Philipp ; Becker, Frank ; Wülfing, Christian ; Barth, Peter ; Stöckle, Michael ; Staehler, Michael ; Stief, Christian ; Haferkamp, Axel ; Hohenfellner, Markus ; Macher-Göppinger, Stephan ; Wullich, Bernd ; Noldus, Joachim ; Brenner, Walburgis ; Roos, Frederik C. ; Walter, Bernhard ; Otto, Wolfgang ; Burger, Maximilian ; Schrader, Andres Jan ; Hartmann, Arndt ; Mondorf, Yvonne ; Ivanyi, Philipp ; Mikuteit, Marie ; Steffens, Sandra</creator><creatorcontrib>Erlmeier, Franziska ; Bruecher, Benedict ; Stöhr, Christine ; Herrmann, Edwin ; Polifka, Iris ; Agaimy, Abbas ; Trojan, Lutz ; Ströbel, Philipp ; Becker, Frank ; Wülfing, Christian ; Barth, Peter ; Stöckle, Michael ; Staehler, Michael ; Stief, Christian ; Haferkamp, Axel ; Hohenfellner, Markus ; Macher-Göppinger, Stephan ; Wullich, Bernd ; Noldus, Joachim ; Brenner, Walburgis ; Roos, Frederik C. ; Walter, Bernhard ; Otto, Wolfgang ; Burger, Maximilian ; Schrader, Andres Jan ; Hartmann, Arndt ; Mondorf, Yvonne ; Ivanyi, Philipp ; Mikuteit, Marie ; Steffens, Sandra ; German Network Of Kidney Cancer</creatorcontrib><description>The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET− vs. cMET+: pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET−: 2 [4.3%] vs. cMET+: 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival.
•The tyrosine-protein kinase c-Met supports aggressive tumor behavior and plays a decisive role in numerous cellular processes.•Patients' medical history and tumor specimens were collected from n = 197 and n = 110 patients with type 1 and 2 papillary renal cell carcinoma, respectively.•cMET expression did not qualify as a prognostic marker in papillary renal cell carcinoma for overall survival.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2021.12.007</identifier><identifier>PMID: 34998840</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Carcinoma, Renal Cell - pathology ; cMET ; Cohort Studies ; Cytoplasm ; Disease ; FDA approval ; Female ; Humans ; Immunohistochemistry ; Kidney cancer ; Kidney Neoplasms - pathology ; Kinases ; Male ; Medical prognosis ; Mutation ; Outcome ; Papillary renal cell carcinoma ; Patients ; Prognosis ; Proto-Oncogene Proteins c-met - metabolism ; Survival ; Tumors</subject><ispartof>Human pathology, 2022-03, Vol.121, p.1-10</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><rights>2021. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-c87541c9d00ac919795c1dadfcdf2ec4d43db9a6a69a5e3424f6ba3dd8db0b8d3</citedby><cites>FETCH-LOGICAL-c393t-c87541c9d00ac919795c1dadfcdf2ec4d43db9a6a69a5e3424f6ba3dd8db0b8d3</cites><orcidid>0000-0002-8095-3586 ; 0000-0002-1511-6212 ; 0000-0002-6513-2894 ; 0000-0002-2862-7302 ; 0000-0001-8546-0548 ; 0000-0003-3291-9460</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.humpath.2021.12.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34998840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Erlmeier, Franziska</creatorcontrib><creatorcontrib>Bruecher, Benedict</creatorcontrib><creatorcontrib>Stöhr, Christine</creatorcontrib><creatorcontrib>Herrmann, Edwin</creatorcontrib><creatorcontrib>Polifka, Iris</creatorcontrib><creatorcontrib>Agaimy, Abbas</creatorcontrib><creatorcontrib>Trojan, Lutz</creatorcontrib><creatorcontrib>Ströbel, Philipp</creatorcontrib><creatorcontrib>Becker, Frank</creatorcontrib><creatorcontrib>Wülfing, Christian</creatorcontrib><creatorcontrib>Barth, Peter</creatorcontrib><creatorcontrib>Stöckle, Michael</creatorcontrib><creatorcontrib>Staehler, Michael</creatorcontrib><creatorcontrib>Stief, Christian</creatorcontrib><creatorcontrib>Haferkamp, Axel</creatorcontrib><creatorcontrib>Hohenfellner, Markus</creatorcontrib><creatorcontrib>Macher-Göppinger, Stephan</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Noldus, Joachim</creatorcontrib><creatorcontrib>Brenner, Walburgis</creatorcontrib><creatorcontrib>Roos, Frederik C.</creatorcontrib><creatorcontrib>Walter, Bernhard</creatorcontrib><creatorcontrib>Otto, Wolfgang</creatorcontrib><creatorcontrib>Burger, Maximilian</creatorcontrib><creatorcontrib>Schrader, Andres Jan</creatorcontrib><creatorcontrib>Hartmann, Arndt</creatorcontrib><creatorcontrib>Mondorf, Yvonne</creatorcontrib><creatorcontrib>Ivanyi, Philipp</creatorcontrib><creatorcontrib>Mikuteit, Marie</creatorcontrib><creatorcontrib>Steffens, Sandra</creatorcontrib><creatorcontrib>German Network Of Kidney Cancer</creatorcontrib><title>cMET: a prognostic marker in papillary renal cell carcinoma?</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET− vs. cMET+: pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET−: 2 [4.3%] vs. cMET+: 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival.
•The tyrosine-protein kinase c-Met supports aggressive tumor behavior and plays a decisive role in numerous cellular processes.•Patients' medical history and tumor specimens were collected from n = 197 and n = 110 patients with type 1 and 2 papillary renal cell carcinoma, respectively.•cMET expression did not qualify as a prognostic marker in papillary renal cell carcinoma for overall survival.</description><subject>Carcinoma, Renal Cell - pathology</subject><subject>cMET</subject><subject>Cohort Studies</subject><subject>Cytoplasm</subject><subject>Disease</subject><subject>FDA approval</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kinases</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>Outcome</subject><subject>Papillary renal cell carcinoma</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins c-met - metabolism</subject><subject>Survival</subject><subject>Tumors</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLxDAQx4Mouj4-glLw4qU1r6aJCIssvmDFi55DmqSatS-TVthvb8quHrx4mbn8ZuY_PwBOEcwQROxylb2PTa-G9wxDjDKEMwiLHTBDOcEpJwLvghmElKUcFcUBOAxhBSFCOc33wQGhQnBO4Qxc66fbl6tEJb3v3touDE4njfIf1ieuTXrVu7pWfp1426o60baORXnt2q5R82OwV6k62JNtPwKvd7cvi4d0-Xz_uLhZppoIMqSaFzlFWhgIlRZIFCLXyChTaVNhq6mhxJRCMcWEyi2hmFasVMQYbkpYckOOwMVmbwz5OdowyMaFKYtqbTcGiRnieXyTsYie_0FX3ehj9okiXDAqKI9UvqG070LwtpK9d_HttURQTnrlSm71ykmvRFhGvXHubLt9LBtrfqd-fEZgvgFs1PHlrJdBO9tqa5y3epCmc_-c-AZlF42l</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Erlmeier, Franziska</creator><creator>Bruecher, Benedict</creator><creator>Stöhr, Christine</creator><creator>Herrmann, Edwin</creator><creator>Polifka, Iris</creator><creator>Agaimy, Abbas</creator><creator>Trojan, Lutz</creator><creator>Ströbel, Philipp</creator><creator>Becker, Frank</creator><creator>Wülfing, Christian</creator><creator>Barth, Peter</creator><creator>Stöckle, Michael</creator><creator>Staehler, Michael</creator><creator>Stief, Christian</creator><creator>Haferkamp, Axel</creator><creator>Hohenfellner, Markus</creator><creator>Macher-Göppinger, Stephan</creator><creator>Wullich, Bernd</creator><creator>Noldus, Joachim</creator><creator>Brenner, Walburgis</creator><creator>Roos, Frederik C.</creator><creator>Walter, Bernhard</creator><creator>Otto, Wolfgang</creator><creator>Burger, Maximilian</creator><creator>Schrader, Andres Jan</creator><creator>Hartmann, Arndt</creator><creator>Mondorf, Yvonne</creator><creator>Ivanyi, Philipp</creator><creator>Mikuteit, Marie</creator><creator>Steffens, Sandra</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8095-3586</orcidid><orcidid>https://orcid.org/0000-0002-1511-6212</orcidid><orcidid>https://orcid.org/0000-0002-6513-2894</orcidid><orcidid>https://orcid.org/0000-0002-2862-7302</orcidid><orcidid>https://orcid.org/0000-0001-8546-0548</orcidid><orcidid>https://orcid.org/0000-0003-3291-9460</orcidid></search><sort><creationdate>202203</creationdate><title>cMET: a prognostic marker in papillary renal cell carcinoma?</title><author>Erlmeier, Franziska ; Bruecher, Benedict ; Stöhr, Christine ; Herrmann, Edwin ; Polifka, Iris ; Agaimy, Abbas ; Trojan, Lutz ; Ströbel, Philipp ; Becker, Frank ; Wülfing, Christian ; Barth, Peter ; Stöckle, Michael ; Staehler, Michael ; Stief, Christian ; Haferkamp, Axel ; Hohenfellner, Markus ; Macher-Göppinger, Stephan ; Wullich, Bernd ; Noldus, Joachim ; Brenner, Walburgis ; Roos, Frederik C. ; Walter, Bernhard ; Otto, Wolfgang ; Burger, Maximilian ; Schrader, Andres Jan ; Hartmann, Arndt ; Mondorf, Yvonne ; Ivanyi, Philipp ; Mikuteit, Marie ; Steffens, Sandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-c87541c9d00ac919795c1dadfcdf2ec4d43db9a6a69a5e3424f6ba3dd8db0b8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Carcinoma, Renal Cell - pathology</topic><topic>cMET</topic><topic>Cohort Studies</topic><topic>Cytoplasm</topic><topic>Disease</topic><topic>FDA approval</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kinases</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>Outcome</topic><topic>Papillary renal cell carcinoma</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins c-met - metabolism</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erlmeier, Franziska</creatorcontrib><creatorcontrib>Bruecher, Benedict</creatorcontrib><creatorcontrib>Stöhr, Christine</creatorcontrib><creatorcontrib>Herrmann, Edwin</creatorcontrib><creatorcontrib>Polifka, Iris</creatorcontrib><creatorcontrib>Agaimy, Abbas</creatorcontrib><creatorcontrib>Trojan, Lutz</creatorcontrib><creatorcontrib>Ströbel, Philipp</creatorcontrib><creatorcontrib>Becker, Frank</creatorcontrib><creatorcontrib>Wülfing, Christian</creatorcontrib><creatorcontrib>Barth, Peter</creatorcontrib><creatorcontrib>Stöckle, Michael</creatorcontrib><creatorcontrib>Staehler, Michael</creatorcontrib><creatorcontrib>Stief, Christian</creatorcontrib><creatorcontrib>Haferkamp, Axel</creatorcontrib><creatorcontrib>Hohenfellner, Markus</creatorcontrib><creatorcontrib>Macher-Göppinger, Stephan</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Noldus, Joachim</creatorcontrib><creatorcontrib>Brenner, Walburgis</creatorcontrib><creatorcontrib>Roos, Frederik C.</creatorcontrib><creatorcontrib>Walter, Bernhard</creatorcontrib><creatorcontrib>Otto, Wolfgang</creatorcontrib><creatorcontrib>Burger, Maximilian</creatorcontrib><creatorcontrib>Schrader, Andres Jan</creatorcontrib><creatorcontrib>Hartmann, Arndt</creatorcontrib><creatorcontrib>Mondorf, Yvonne</creatorcontrib><creatorcontrib>Ivanyi, Philipp</creatorcontrib><creatorcontrib>Mikuteit, Marie</creatorcontrib><creatorcontrib>Steffens, Sandra</creatorcontrib><creatorcontrib>German Network Of Kidney Cancer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erlmeier, Franziska</au><au>Bruecher, Benedict</au><au>Stöhr, Christine</au><au>Herrmann, Edwin</au><au>Polifka, Iris</au><au>Agaimy, Abbas</au><au>Trojan, Lutz</au><au>Ströbel, Philipp</au><au>Becker, Frank</au><au>Wülfing, Christian</au><au>Barth, Peter</au><au>Stöckle, Michael</au><au>Staehler, Michael</au><au>Stief, Christian</au><au>Haferkamp, Axel</au><au>Hohenfellner, Markus</au><au>Macher-Göppinger, Stephan</au><au>Wullich, Bernd</au><au>Noldus, Joachim</au><au>Brenner, Walburgis</au><au>Roos, Frederik C.</au><au>Walter, Bernhard</au><au>Otto, Wolfgang</au><au>Burger, Maximilian</au><au>Schrader, Andres Jan</au><au>Hartmann, Arndt</au><au>Mondorf, Yvonne</au><au>Ivanyi, Philipp</au><au>Mikuteit, Marie</au><au>Steffens, Sandra</au><aucorp>German Network Of Kidney Cancer</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>cMET: a prognostic marker in papillary renal cell carcinoma?</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>121</volume><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET− vs. cMET+: pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET−: 2 [4.3%] vs. cMET+: 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival.
•The tyrosine-protein kinase c-Met supports aggressive tumor behavior and plays a decisive role in numerous cellular processes.•Patients' medical history and tumor specimens were collected from n = 197 and n = 110 patients with type 1 and 2 papillary renal cell carcinoma, respectively.•cMET expression did not qualify as a prognostic marker in papillary renal cell carcinoma for overall survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34998840</pmid><doi>10.1016/j.humpath.2021.12.007</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8095-3586</orcidid><orcidid>https://orcid.org/0000-0002-1511-6212</orcidid><orcidid>https://orcid.org/0000-0002-6513-2894</orcidid><orcidid>https://orcid.org/0000-0002-2862-7302</orcidid><orcidid>https://orcid.org/0000-0001-8546-0548</orcidid><orcidid>https://orcid.org/0000-0003-3291-9460</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0046-8177 |
| ispartof | Human pathology, 2022-03, Vol.121, p.1-10 |
| issn | 0046-8177 1532-8392 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2618517766 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Carcinoma, Renal Cell - pathology cMET Cohort Studies Cytoplasm Disease FDA approval Female Humans Immunohistochemistry Kidney cancer Kidney Neoplasms - pathology Kinases Male Medical prognosis Mutation Outcome Papillary renal cell carcinoma Patients Prognosis Proto-Oncogene Proteins c-met - metabolism Survival Tumors |
| title | cMET: a prognostic marker in papillary renal cell carcinoma? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T13%3A27%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=cMET:%20a%20prognostic%20marker%20in%20papillary%20renal%20cell%20carcinoma?&rft.jtitle=Human%20pathology&rft.au=Erlmeier,%20Franziska&rft.aucorp=German%20Network%20Of%20Kidney%20Cancer&rft.date=2022-03&rft.volume=121&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2021.12.007&rft_dat=%3Cproquest_cross%3E2618517766%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638964948&rft_id=info:pmid/34998840&rft_els_id=S004681772100215X&rfr_iscdi=true |